Zydus Lifesciences Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 100% at ₹1/Share	24-Jul-2026	24-Jul-2026
DividendsFinal Dividend of 1100% at ₹11/Share	25-Jul-2025	25-Jul-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Parag Parikh Flexi Cap Fund - Regular Plan - Growth	1.93 Cr	1.93 Cr no change
Kotak Flexi Cap Fund - Growth	1.04 Cr	1.04 Cr no change
HSBC Midcap Fund - Regular Plan - Growth	29.33 Lac	40.79 Lac (39.07%)
Bandhan Large & Mid Cap Fund - Regular Plan - Growth	20.19 Lac	29.58 Lac (46.46%)
ICICI Prudential Large Cap Fund - Growth	24.81 Lac	24.81 Lac no change

RAJIV GUPTA (SEBI RA)

15 Oct • 1:18 PM · SEBI-Registered Analyst

Zydus Sunshine Lifesciences signs agreement

ZYDUSLIFE

Zydus Lifesciences Limited's Zydus Sunshine Lifesciences (Pvt) Ltd, the proposed joint venture between Zydus Lifesciences Limited (Zydus) and Sunshine Healthcare, part of Sunshine Holdings PLC, signed an agreement with the Board of Investment of Sri Lanka on 13 October 2026 to establish a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka. Both companies had announced the formation of a Joint Venture on 26 June 2026. The project envisages a phased investment of over USD 20 million. The facility will be developed on a site of nearly four acres, with commercial operations expected to commence in 2028, subject to project timelines and relevant regulatory approvals. Opinion : This will have positive impact on the stock price. Disclaimer : This is not a but sell or hold recommendation. I do not hold this stock

CA Barkha Kamra

15 Oct • 12:07 PM · SEBI-Registered Analyst

Zydus Signs Sri Lanka Pharmaceutical Facility Deal

Zydus Lifesciences Ltd

ZYDUSLIFE

has signed an agreement with the Board of Investment (BOI), Sri Lanka, to establish a pharmaceutical manufacturing facility in the country. The proposed project involves an investment of over USD 20 million (approximately ₹180 crore), with commercial operations expected to commence in 2028. Key Highlights: * Strategic Expansion: The investment represents an important step in Zydus Lifesciences’ international expansion strategy, strengthening its manufacturing presence beyond India. * Investment Commitment: The company plans to invest more than USD 20 million in developing pharmaceutical manufacturing infrastructure in Sri Lanka. * Operational Timeline: The facility is expected to become operational in 2028, indicating a medium-term investment horizon. * Market Opportunity: The project could help Zydus strengthen its presence in Sri Lanka’s pharmaceutical market, improve local medicine availability and potentially reduce dependence on imported pharmaceutical products. * Economic Benefits: The proposed facility could support employment generation, technology transfer, local manufacturing capabilities and development of Sri Lanka’s pharmaceutical ecosystem. Business and Financial Implications: The investment is strategically positive for Zydus Lifesciences as it could diversify the company’s geographical manufacturing footprint and create opportunities for long-term revenue growth. However, the immediate financial impact is expected to be limited, given the project’s planned operational commencement in 2028. Future contributions will depend on production capacity, product portfolio, regulatory approvals and market demand.

Saurab Jain

14 Oct • 11:11 PM · SEBI-Registered Analyst

Zydus Lifesciences falls 0.7% after USFDA plant inspection

Zydus Lifesciences fell 0.69% after a USFDA inspection at Moraiya ended with five observations, with support at Rs 1,085 and Rs 1,050. Zydus Lifesciences Limited [

ZYDUSLIFE

] closed 0.69% lower at Rs 1,124.70 on 14 October, a day after the USFDA inspection of its Moraiya plant in Ahmedabad ended with five observations. The inspection ran from 5 to 13 October. The company did not disclose what the observations were and said it will work with the USFDA to address them quickly. Observations are a written list of issues to fix and carry no penalty on their own. The market now waits for the severity of the findings and the company’s response, since the plant supplies the US market. The stock is range-bound. It has traded between about Rs 1,085 and Rs 1,232 since July. Immediate support is Rs 1,085, with key support at Rs 1,050. Resistance is Rs 1,232. RSI is 44.59, below its average of 51.44, so momentum is soft. A close below Rs 1,085 would put Rs 1,050 in play, and a close below Rs 1,050 would open a deeper fall. A close above Rs 1,232 would end the range to the upside. Disclosure: I do not hold any position in this stock. This is not a recommendation to buy or sell. Investments in securities markets are subject to market risks. Read all related documents carefully before investing.

Finkhoz Roboadvisory Services

14 Oct • 4:11 PM · SEBI-Registered Analyst

Zydus Lifesciences slips 2% on five USFDA observations

ZYDUSLIFE

(ZYDUSLIFE) fell 2.1% to ₹1,109 in early trade on October 14, after a USFDA inspection of its Moraiya, Ahmedabad plant ended with five observations. The stock had closed at ₹1,131 on the BSE on October 13. The inspection ran from October 5 to October 13, 2026, and the company said it will work with the USFDA to address the observations quickly. On the same day, Zydus and partner Formycon AG said the USFDA had accepted their application for FYB206, a proposed biosimilar to the cancer drug Keytruda (pembrolizumab), for review. The two updates pull in opposite directions. Observations at a US-facing plant can delay approvals or raise compliance costs, depending on how serious they are. The FYB206 acceptance is a longer-term positive. Keytruda is one of the world's top-selling cancer drugs, and Zydus holds exclusive rights in the US and Canada. Bernstein sees about 29% upside, saying the acceptance reinforces its investment view. Neither event is final yet. The nature of the five observations is not disclosed, so it is unclear whether they are procedural or serious. The FYB206 decision is not expected until around the third quarter of 2027, based on the 12-month review timeline. Meanwhile, North America formulation sales fell 2.6% year-on-year last quarter, so the US business needs new growth drivers. Investors should watch the USFDA's final classification of the Moraiya inspection, any warning letter or import alert, FYB206's review progress, and US sales trends in Q2 FY27 results. The key question is whether the plant observations get resolved without disrupting the US pipeline. Disclosure: I do not hold any position in Zydus Lifesciences Limited. This post is for informational purposes only and is not investment advice.

Manish Salvi

14 Oct • 8:58 AM · SEBI-Registered Analyst

Zydus Lifesciences in focus after USFDA inspection

Zydus Lifesciences Limited shares are in focus after a USFDA inspection of its Moraiya facility ended with five observations. Support is Rs 1,085 to Rs 1,095. Zydus Lifesciences Limited [

ZYDUSLIFE

] is in focus after a US Food and Drug Administration inspection of its manufacturing facility in Moraiya, Ahmedabad, ended with five observations. The inspection ran from 5 October to 13 October. Observations are points raised at the end of an inspection, and the company can respond to them. The update gives no detail on their nature or effect on operations. The stock traded at Rs 1,132.50, down 0.17%, below its moving average of Rs 1,152.50. It has ranged since July, and the Rs 1,085 to Rs 1,095 zone held on earlier tests. The RSI reads 46.34, below its average of 52.39, which shows middling momentum. In my view, the stock is moving sideways between support and resistance, and the news adds no clear direction on its own. The Rs 1,085 to Rs 1,095 zone is the strong support, and a fall below it would put lower levels in view. The Rs 1,205 to Rs 1,233 zone is the resistance, and a move above it would bring fresh highs into focus. Neutral stance while price trades between Rs 1,095 and Rs 1,205. Disclaimer: I do not hold any position in this. This content is for informational purposes only and is not a recommendation to buy or sell. Investments in securities are subject to market risks. Please read all related documents carefully before investing.

MNC RESEARCH

8 Oct • 10:28 AM · SEBI-Registered Analyst

PHARMA SECTOR SHOWING SUPER STRENGTH AMID WEAKER MARKETS

One interesting trend in the current market is the relative strength being displayed by Pharma stocks. During the COVID period, Pharma stocks had a completely different story. Despite many companies having strong fundamentals and robust businesses, the sector witnessed significant selling and several quality Pharma stocks were beaten down heavily once the initial COVID euphoria faded. Fast forward to today — the scenario looks very different. While the broader market is facing pressure, several Pharma stocks are holding their ground and continuing to show strong price action. Stocks like Divi’s Labs, Laurus Labs, Torrent Pharma, Zydus Lifesciences, Sun Pharma and Lupin are among the names showing encouraging strength. For me, the important takeaway is not simply that Pharma is rising — it is that Pharma is showing strength when the broader market is weak. That kind of relative strength often deserves attention. When the market becomes volatile, sectors that refuse to participate in the downside can potentially become the leaders when market sentiment improves. Pharma is definitely a sector I would keep on the radar for momentum and swing-trading opportunities.

Zydus Lifesciences Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Zydus Lifesciences Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Zydus Lifesciences Ltd.?

What is the market cap of Zydus Lifesciences Ltd.?

Should I buy Zydus Lifesciences Ltd. stock now?

What is the 52 week high and low of Zydus Lifesciences Ltd.?

Is the Zydus Lifesciences Ltd. stock good to buy?

Is Zydus Lifesciences Ltd. a good buy for the long term?

Is Zydus Lifesciences Ltd. overvalued or undervalued?

What is the PE and PB ratio of Zydus Lifesciences Ltd.?